Literature DB >> 22358264

Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON.

S Daenen, B van der Holt, A W Dekker, R Willemze, A W Rijneveld, B J Biemond, P Muus, A A van de Loosdrecht, H C Schouten, M van Marwijk Kooy, D A Breems, H Demuynck, J Maertens, P W Wijermans, S Wittebol, E W de Klerk, J J Cornelissen.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22358264     DOI： 10.1038/leu.2012.53

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.

Authors:  Judith M Boer; Jasper E Koenders; Bronno van der Holt; Carla Exalto; Mathijs A Sanders; Jan J Cornelissen; Peter J M Valk; Monique L den Boer; Anita W Rijneveld
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

Review 2.  Recent advances and novel treatment paradigms in acute lymphocytic leukemia.

Authors:  Nikolaos Papadantonakis; Anjali S Advani
Journal:  Ther Adv Hematol       Date:  2016-06-29

3.  Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival.

Authors:  A G Dinmohamed; A Szabó; M van der Mark; O Visser; P Sonneveld; J J Cornelissen; M Jongen-Lavrencic; A W Rijneveld
Journal:  Leukemia       Date:  2015-08-19       Impact factor: 11.528

Review 4.  The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.

Authors:  Victor D Fedorov; Vivek A Upadhyay; Amir T Fathi
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

5.  Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity.

Authors:  C Batenchuk; F Le Boeuf; L Stubbert; T Falls; H L Atkins; J C Bell; D P Conrad
Journal:  Blood Cancer J       Date:  2013-07-12       Impact factor: 11.037

6.  Oral Mucormycosis and Aspergillosis in the Patient with Acute Leukemia.

Authors:  Vanja Vučićević Boras; Martin Jurlina; Vlaho Brailo; Katarina Đurić Vuković; Pavle Rončević; Sandra Bašić Kinda; Danica Vidović Juras; Dragana Gabrić
Journal:  Acta Stomatol Croat       Date:  2019-09

7.  Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.

Authors:  Anita W Rijneveld; Bronno van der Holt; Okke de Weerdt; Bart J Biemond; Arjen A van de Loosdrecht; Lotte E van der Wagen; Mar Bellido; Michel van Gelder; Walter J F M van der Velden; Dominik Selleslag; Daniëlle van Lammeren-Venema; Constantijn J M Halkes; Rob Fijnheer; Violaine Havelange; Geerte L van Sluis; Marie-Cecile Legdeur; Dries Deeren; Alain Gadisseur; Harm A M Sinnige; Dimitri A Breems; Aurélie Jaspers; Ollivier Legrand; Wim E Terpstra; Rinske S Boersma; Dominiek Mazure; Agnes Triffet; Lidwine W Tick; Karolien Beel; Johan A Maertens; H Berna Beverloo; Marleen Bakkus; Christa H E Homburg; Valerie de Haas; Vincent H J van der Velden; Jan J Cornelissen
Journal:  Blood Adv       Date:  2022-02-22

8.  Effect of leaving chronic oral foci untreated on infectious complications during intensive chemotherapy.

Authors:  J M Schuurhuis; L F R Span; M A Stokman; A J van Winkelhoff; A Vissink; F K L Spijkervet
Journal:  Br J Cancer       Date:  2016-03-22       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.